-
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
Monday, April 10, 2023 - 8:10am | 751Read More...The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period. A burgeoning sector within biotech is the cell and gene therapy (C>) market. The...
-
Cryoport: Temperature-Controlled Supply Chain Solutions Provider Sees Almost 30% Bump In Revenues
Monday, April 3, 2023 - 8:19am | 192Read More...Robert Stefanovich, CFO of Cryoport, Inc. (NASDAQ: CYRX), was recently a guest on Benzinga’s All-Access. Cryoport is a leading provider of temperature-controlled supply chain solutions for the life sciences and biopharma industries. The company provides end-to-end solutions for clients...
-
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Wednesday, March 15, 2023 - 8:03am | 1035Read More...Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. By offering a platform of end-to-end, fast and technologically advanced packaging and logistics services, Cryoport has filled a key need supporting cell and gene...
-
CryoPort Names Michael Bartholomew as Chief Commercialization Officer
Monday, September 13, 2010 - 8:15am | 163Read More...CryoPort, Inc. (OTCBB: CYRX) today announced that it has named Michael Bartholomew as Chief Commercialization Officer. Mr. Bartholomew has 20 years experience in marketing, sales and sales management in the pharmaceuticals and materials industries. “Michael has an outstanding track record of...
